These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 28279492)

  • 1. Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease.
    Eastman JJ; Cavagnero KJ; Deconde AS; Kim AS; Karta MR; Broide DH; Zuraw BL; White AA; Christiansen SC; Doherty TA
    J Allergy Clin Immunol; 2017 Jul; 140(1):101-108.e3. PubMed ID: 28279492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower serum 15-HETE level predicts nasal ILC2 accumulation during COX-1 inhibition in AERD.
    Badrani JH; Cavagnero K; Eastman JJ; Kim AS; Strohm A; Yan C; Deconde A; Zuraw BL; White AA; Christiansen SC; Doherty TA
    J Allergy Clin Immunol; 2023 Nov; 152(5):1330-1335.e1. PubMed ID: 37543185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease.
    Buchheit KM; Cahill KN; Katz HR; Murphy KC; Feng C; Lee-Sarwar K; Lai J; Bhattacharyya N; Israel E; Boyce JA; Laidlaw TM
    J Allergy Clin Immunol; 2016 May; 137(5):1566-1576.e5. PubMed ID: 26691435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of group 2 innate lymphocytes in aspirin-exacerbated respiratory disease pathogenesis.
    White AA; Doherty TA
    Am J Rhinol Allergy; 2018 Jan; 32(1):7-11. PubMed ID: 29336282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eosinophil production of prostaglandin D
    Feng X; Ramsden MK; Negri J; Baker MG; Payne SC; Borish L; Steinke JW
    J Allergy Clin Immunol; 2016 Oct; 138(4):1089-1097.e3. PubMed ID: 27423494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic expression of inflammatory mediators in patients with chronic rhinosinusitis and nasal polyps with and without Aspirin Exacerbated Respiratory Disease.
    Pezato R; Świerczyńska-Krępa M; Niżankowska-Mogilnicka E; Holtappels G; De Ruyck N; Sanak M; Derycke L; Van Crombruggen K; Bachert C; Pérez-Novo CA
    Cytokine; 2016 Jan; 77():157-67. PubMed ID: 26615369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A trial of type 12 purinergic (P2Y
    Laidlaw TM; Cahill KN; Cardet JC; Murphy K; Cui J; Dioneda B; Kothari P; Raby BA; Israel E; Boyce JA
    J Allergy Clin Immunol; 2019 Jan; 143(1):316-324.e7. PubMed ID: 29890239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-mediated innate lymphoid cell recruitment and activation in aspirin-exacerbated respiratory disease.
    Cavagnero KJ; Doherty TA
    Ann Allergy Asthma Immunol; 2021 Feb; 126(2):135-142. PubMed ID: 32950684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease.
    Laidlaw TM; Buchheit KM; Cahill KN; Hacker J; Cho L; Cui J; Feng C; Chen CC; Le M; Israel E; Boyce JA
    J Allergy Clin Immunol; 2023 Sep; 152(3):700-710.e3. PubMed ID: 37068712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mediator production and severity of aspirin-induced respiratory reactions: Impact of sampling site and body mass index.
    Cahill KN; Wu P; Milne GL; Amin T; Singer J; Murphy K; Lewis E; Gapko D; Boyce JA; Buchheit KM; Laidlaw TM
    J Allergy Clin Immunol; 2022 Jul; 150(1):170-177.e6. PubMed ID: 35026207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin provocation increases 8-iso-PGE2 in exhaled breath condensate of aspirin-hypersensitive asthmatics.
    Mastalerz L; Januszek R; Kaszuba M; Wójcik K; Celejewska-Wójcik N; Gielicz A; Plutecka H; Oleś K; Stręk P; Sanak M
    Prostaglandins Other Lipid Mediat; 2015 Sep; 121(Pt B):163-9. PubMed ID: 26209241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis.
    Bochenek G; Kuschill-Dziurda J; Szafraniec K; Plutecka H; Szczeklik A; Nizankowska-Mogilnicka E
    J Allergy Clin Immunol; 2014 Jan; 133(1):98-103.e1-6. PubMed ID: 23993879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity.
    Mastalerz L; Celejewska-Wójcik N; Wójcik K; Gielicz A; Januszek R; Cholewa A; Stręk P; Sanak M
    Allergy; 2014 Nov; 69(11):1550-9. PubMed ID: 25123806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low E-prostanoid 2 receptor levels and deficient induction of the IL-1β/IL-1 type I receptor/COX-2 pathway: Vicious circle in patients with aspirin-exacerbated respiratory disease.
    Machado-Carvalho L; Martín M; Torres R; Gabasa M; Alobid I; Mullol J; Pujols L; Roca-Ferrer J; Picado C
    J Allergy Clin Immunol; 2016 Jan; 137(1):99-107.e7. PubMed ID: 26560040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sinus Surgery Is Associated with a Decrease in Aspirin-Induced Reaction Severity in Patients with Aspirin Exacerbated Respiratory Disease.
    Jerschow E; Edin ML; Chi Y; Hurst B; Abuzeid WM; Akbar NA; Gibber M; Fried MP; Han W; Pelletier T; Ren Z; Keskin T; Roizen G; Lih FB; Gruzdev A; Bradbury JA; Schuster V; Spivack S; Rosenstreich D; Zeldin DC
    J Allergy Clin Immunol Pract; 2019; 7(5):1580-1588. PubMed ID: 30580047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular interactions in aspirin-exacerbated respiratory disease.
    Badrani JH; Doherty TA
    Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):65-70. PubMed ID: 33306487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease.
    Mitsui C; Kajiwara K; Hayashi H; Ito J; Mita H; Ono E; Higashi N; Fukutomi Y; Sekiya K; Tsuburai T; Akiyama K; Yamamoto K; Taniguchi M
    J Allergy Clin Immunol; 2016 Feb; 137(2):400-11. PubMed ID: 26194538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab can inhibit respiratory reaction during aspirin desensitization.
    Lang DM; Aronica MA; Maierson ES; Wang XF; Vasas DC; Hazen SL
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):98-104. PubMed ID: 29777744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease.
    Buchheit KM; Lewis E; Gakpo D; Hacker J; Sohail A; Taliaferro F; Berreondo Giron E; Asare C; Vukovic M; Bensko JC; Dwyer DF; Shalek AK; Ordovas-Montanes J; Laidlaw TM
    J Allergy Clin Immunol; 2021 Aug; 148(2):574-584. PubMed ID: 34144111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of interleukin-25 levels with development of aspirin induced respiratory diseases.
    Lee JU; Chang HS; Lee HJ; Bae DJ; Son JH; Park JS; Choi JS; Hwang HG; Park CS
    Respir Med; 2017 Feb; 123():71-78. PubMed ID: 28137499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.